I'm LongbridgeAI, I can summarize articles.Merck (MRK) added 0.9% for the week, closing at $145.60 and trailing the S&P 500 by about 0.25 percentage points. The pattern was a late-week recovery rather than a straight climb: shares opened Monday weak and touched a weekly low of $138.80, then ground higher through the following sessions before Friday’s stronger close pushed the week into positive territory. The stock traded within a $138.80–$146.68 range and ended the week back above its 20-day moving average of $145.
The Week
Merck (MRK) added 0.9% for the week, closing at $145.60 and trailing the S&P 500 by about 0.25 percentage points. The pattern was a late-week recovery rather than a straight climb: shares opened Monday weak and touched a weekly low of $138.80, then ground higher through the following sessions before Friday’s stronger close pushed the week into positive territory. The stock traded within a $138.80–$146.68 range and ended the week back above its 20-day moving average of $145.82, still roughly 7.8% below the August peak of $156.92.
Key Events
The news flow concentrated on the oncology pipeline and partner ties. Early in the week the tone was defensive, with Merck shares down 3.04% on Monday as Vaxcyte’s vaccine candidate drew comparisons with Pfizer and Merck. The middle of the week brought denser headlines: Tempus announced a multi-year collaboration with Moderna and Merck around commercialisation support for the V940 melanoma vaccine, while Halozyme won a Dutch court injunction blocking Merck’s Keytruda SC in eight European markets on a patent claim. Separately, commentary asked whether drug approvals could shift Merck’s narrative, though no formal approval landed during the week. Net-net, company-specific action leaned constructive while the patent and competitive threads worked as offsets.
Analyst Ratings
Across 27 institutions covering the stock, 14 rate it buy, 5 rate it overweight and 8 hold, with no sell or underweight ratings. The consensus rating is buy, and the consensus target of $158.28 sits about 8.7% above the latest close. The target range is wide, from $105 to $186, suggesting meaningful dispersion. Within a peer group of 203 pharma names, Merck ranks 4th by analyst coverage count, putting it near the top of the table.
The Week Ahead
The most immediate macro inputs are US CPI and core CPI, both due on Wednesday, 14 October, with consensus forecasts already split on direction. More important for Merck is the fiscal third-quarter earnings release before the open on Thursday, 29 October, where consensus models expect EPS of $1.873 on revenue of $17.3 billion. This week’s two competing threads — the European patent ruling on Keytruda SC and the V940 vaccine collaboration — will be the key questions to watch for on the earnings call.
In Short
This week leaves Merck in a slightly uneven spot: the stock finished modestly higher after a shaky start, the sell-side skew is positive with a consensus target above spot, and the latest session showed large-lot net buying against smaller-lot outflows. The patent ruling and vaccine competition are short-term noise layered on top of an unproven earnings outlook ahead of the Q3 print. The central tension is that valuations are not cheap and target dispersion is wide, yet the consensus rating remains buy.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.